Stefaneanu L, Kovacs K, Horvath E, Lloyd R V, Buchfelder M, Fahlbusch R, Smyth H
Department of Pathology, St. Michael's Hospital, Toronto, Ontario, Canada.
J Clin Endocrinol Metab. 1994 Jan;78(1):83-8. doi: 10.1210/jcem.78.1.8288720.
Estrogen receptor (ER) was demonstrated in nontumorous and adenomatous human pituitaries by autoradiography and biochemical assays. In the present study, we investigated ER mRNA by in situ hybridization applied on paraffin section of 9 nontumorous pituitaries obtained at surgery or autopsy and 109 surgically removed adenomas. In nontumorous pituitaries, in situ hybridization combined with immunocytochemistry revealed hybridization signal in GH-, PRL-, ACTH-, TSH-, and LH/FSH-immunoreactive cells, with the highest intensity in PRL-immunoreactive cells. ER mRNA was also localized in Crooke's cells, corticotrophs extending to posterior lobe, cells lining the pars intermedia cavities, and squamous nests of pars tuberalis. The neurohypophysis, endothelium, and connective tissue expressed no ER gene. ER mRNA was present in all adenoma types, including somatotroph, lactotroph, mixed somatotroph-lactotroph, mammosomatotroph, acidophil stem cell, functioning and silent corticotroph, thyrotroph, gonadotroph, null cell adenomas, and oncocytomas. The strongest signal was seen in some lactotroph and mammosomatotroph adenomas. In 9 lactotroph adenomas exposed to bromocriptine (long-acting repeatable injectable form), the hybridization signal was weak or absent, suggesting that suppression of ER gene plays a role in the inhibition of PRL synthesis and tumor growth.
通过放射自显影和生化分析在非肿瘤性和腺瘤性人垂体中证实了雌激素受体（ER）。在本研究中，我们通过原位杂交对9例手术或尸检获得的非肿瘤性垂体石蜡切片和109例手术切除的腺瘤进行了ER mRNA检测。在非肿瘤性垂体中，原位杂交结合免疫细胞化学显示在生长激素（GH）、催乳素（PRL）、促肾上腺皮质激素（ACTH）、促甲状腺激素（TSH）和促黄体生成素/促卵泡生成素（LH/FSH）免疫反应性细胞中有杂交信号，其中PRL免疫反应性细胞中的信号强度最高。ER mRNA也定位于克鲁克细胞、延伸至后叶的促肾上腺皮质激素细胞、中间部腔隙内衬细胞和结节部鳞状细胞巢。神经垂体、内皮和结缔组织不表达ER基因。ER mRNA存在于所有腺瘤类型中，包括生长激素细胞腺瘤、催乳素细胞腺瘤、生长激素-催乳素细胞混合腺瘤、乳腺生长激素细胞腺瘤、嗜酸性干细胞腺瘤、功能性和静止性促肾上腺皮质激素细胞腺瘤、促甲状腺激素细胞腺瘤、促性腺激素细胞腺瘤、无功能细胞腺瘤和嗜酸性细胞瘤。在一些催乳素细胞和乳腺生长激素细胞腺瘤中可见最强信号。在9例接受溴隐亭（长效可重复注射剂型）治疗的催乳素细胞腺瘤中，杂交信号微弱或缺失，提示ER基因的抑制在PRL合成和肿瘤生长的抑制中起作用。
